5.3. muscle-invasive metastatic bladder cancer health status. complications rc may directly related pre-existing comorbidity well surgical procedure, bowel anastomosis, urinary diversion. significant body literature evaluated usefulness age prognostic factor rc, although chronological age less important frailty [159-161]. frailty syndrome reduced ability respond stressors. patients frailty higher risk mortality negative side effects cancer treatment . controversy remains regarding age, rc type urinary diversion. radical cystectomy associated greatest risk reduction disease-related non-disease-related death patients aged < 80 years . largest retrospective study rc septuagenarians octogenarians based data national surgical quality improvement program database (n = 1,710) showed significant difference wound, cardiac, pulmonary complications. however, risk mortality octogenarians compared septuagenarians higher (4.3% vs. 2.3%) . although octogenarians successfully underwent neobladder procedure, patients treated ileal conduit diversion. important evaluate functioning quality life (qol) older patients using standardised geriatric assessment, well carrying standard medical evaluation . sarcopenia shown independent predictor os css large multi-centre study patients undergoing rc bc . order predict csm rc patients receiving nac, sarcopenia assessed completing chemotherapy . risk factors morbidity include prior abdominal surgery, extravesical disease, prior rt . female gender, increased bmi lower pre-operative albumin levels associated higher rate parastomal hernias . low pre-operative serum albumin also associated impaired wound healing, gastrointestinal (gi) complications decrease recurrence-free os rc . therefore, could used prognostic biomarker patients undergoing rc. metformin suggested possibly anticancer activity bladder cancer inhibiting tumour growth well synergistic cisplatin. systematic review meta-analysis 4,006 patients suggests metformin use associated lower cancer specific overall moratlity patients mibc . 5.3.1. evaluation comorbidity, frailty cognition rochon et al., shown evaluation comorbidity provides better indicator life expectancy mibc patient age . evaluation comorbidity helps identify factors likely interfere with, impact on, treatment evolution prognosis mibc . value assessing overall health recommending proceeding surgery emphasised zietman et al., demonstrated association comorbidity adverse pathological survival outcomes following rc . similar results found impact comorbidity cancer-specific other-cause mortality population-based competing risk analysis > 11,260 patients surveillance, epidemiology, end results (seer) registries. age carried highest risk other-cause mortality increased cancer-specific death, stage locally-advanced tumour strongest predictor decreased css . stratifying older patients according frailty using multidisciplinary approach help select patients likely benefit radical surgery optimise treatment outcomes . many different screening tools available frailty local approaches used. examples include g8 clinical frailty scale (see table 5.2 figure 5.1 below). cognitive impairment screened using tool mini-cog (https://mini-cog. com/), consists three-word recall clock-drawing test, completed within 5 minutes. score ≤ 3/5 indicates need refer patient full cognitive assessment. patients form cognitive impairment (e.g., alzheimer’s vascular dementia) may need capacity assessment ability make informed decision, important factor health status assessment. cognitive impairment also predicts risk delirium, important patients undergoing surgery . table 5.2: g8 screening tool (adapted ) itemspossible responses (score)ahas food intake declined past 3 months due loss appetite, digestive problems, chewing, swallowing difficulties?0 = severe decrease food intake1 = moderate decrease food intake2 = decrease food intakebweight loss last 3 months?0 = weight loss > 3 kg1 = know2 = weight loss 1 3 kg3 = weight losscmobility?0 = bed chair bound1 = able get bed/chair go out2 = goes outdneuropsychological problems?0 = severe dementia depression1 = mild dementia2 = psychological problemsebmi? (weight kg)/(height m2)0 = bmi < 191 = bmi 19 < 212 = bmi 21 < 233 = bmi > 23ftakes three prescription drugs per day?0 = yes1 = nogin comparison people age, patient consider his/her health status?0.0 = good0.5 = know1.0 = good2.0 = betterhage0 = > 851 = 80–852 = < 80total score0–17 figure 5.1: clinical frailty scale©, version 2.0* *permission reproduce clinical frailty scale© granted copyright holder. 5.3.2. comorbidity scales, anaesthetic risk classification geriatric assessment range comorbidity scales developed , seven validated [182-188]. charlson comorbidity index (cci) ranges 0 30 according importance comorbidity described four levels calculated healthcare practitioners based patients’ medical records. score widely studied patients bc found independent prognostic factor peri-operative mortality , overall mortality , csm [163,92-194]. age-adjusted version cci correlated cancer-specific other-cause mortality . age-adjusted cci (table 5.3) widely used comorbidity index cancer estimating long-term survival easily calculated . health assessment oncology patients must supplemented measuring activity level. extermann et al., shown correlation morbidity competitive activity level . eastern cooperative oncology group (ecog) performance status (ps) scores karnofsky index validated measure patient activity . performance score correlated patient os rc palliative chemotherapy [199-201]. patients screened positive frailty cognitive impairment benefit assessment geriatrician. allows identification geriatric syndromes scope optimisation. complete protocol comprehensive geriatric assessment (cga) useful care cancer patients . bc, cga used adapt gemcitabine chemotherapy previously untreated older patients advanced bc . table 5.3: calculation charlson comorbidity index number pointsconditions150–60 yearsmyocardial infarctionheart failureperipheral vascular insufficiencycerebrovascular diseasedementiachronic lung diseaseconnective tissue diseaseulcer diseasemild liver diseasediabetes261–70 yearshemiplegiamoderate severe kidney diseasediabetes organ damagetumours origins371–80 yearsmoderate severe liver disease481–90 years5> 90 years6metastatic solid tumoursaids interpretation:1. calculate charlson comorbidity score index = ia. add comorbidity score age scoreb. total denoted ‘i’ charlson probability calculation (see below). = sum comorbidity score age score 2. calculate charlson probability (10-year mortality = y)a. calculate = 10(i x 0.9)b. calculate z = 0.983y (where z 10-year survival) 5.3.3. summary evidence guidelines comorbidity scales summary evidencelechronological age limited relevance.3it important screen frailty cognitive impairment provide comprehensive geriatric assessment (cga) optimisation needed.3 recommendationsstrength ratingbase decision bladder-sparing treatment radical cystectomy older/frail patients invasive bladder cancer tumour stage frailty.strongassess comorbidity validated score, charlson comorbidity index.the american society anesthesiologists score used setting(see section 5.3.2).strong